Marvel Biosciences announced it will present at the 2nd Neuroscience Innovation Partnering & Licensing Summit in Boston on April 29, 2026, highlighting progress on its lead drug candidate MB-204. This drug targets social deficits in disorders like autism, depression, and Alzheimer's by blocking the A2A receptor. Marvel has secured patents in major markets and non-dilutive funding to complete preclinical studies and initiate a Phase 1 clinical trial. The summit offers Marvel a platform to engage potential partners and investors to accelerate development and commercialization of its neurological therapies.
The FTSE 100 index fell slightly, dragged down by mining stocks reacting to China's slower GDP growth of 4.3% in Q2, its weakest in three years. Despite this, oil prices remained steady amid US-Iran tensions. PayPal shares jumped over 14% following r...
The Goldman Sachs Future Tech Leaders Equity ETF (GTEK) has delivered a 48.9% return year-to-date, nearly doubling the 25% return of the Vanguard Information Technology ETF (VGT). Unlike VGT, which heavily invests in mega-cap tech giants like Nvidia,...
